The purpose of the study is to evaluate the safety and effectiveness of SAR448851 in people with early Alzheimer’s disease. Participants will take the study medication every day for about 48 weeks, during which they will have regular visits for simple blood tests that measure a protein called p‑tau217, a marker that can show changes related to the disease, and may also undergo a brain scan to look for amyloid plaques, which are tiny buildups associated with Alzheimer’s. After the first 48 weeks, participants may choose to continue in an open‑label phase, where everyone receives the active medication, for up to another year, with continued monitoring.

Throughout the trial, safety is closely watched by checking for any side effects, measuring vital signs, and performing routine laboratory tests. Any serious problems are recorded, and participants can stop the study at any time if needed.

The purpose of the study is to describe the safety profile of the PG4 vaccine. Infants receive a single dose of either the study vaccine or the comparison vaccine and are then observed for a short time after the injection, followed by scheduled visits to check their health over the next weeks.

Researchers will watch for common side effects such as redness, swelling, pain at the injection site, fever, reduced appetite, irritability, or increased sleep. Any side effects, known as adverse events, and any serious side effects that require medical attention, called serious adverse events, will be recorded and reviewed.

The aim of the study is to determine whether the drug can improve walking capacity in this population. Participants are randomly assigned to receive either the active tablet or the placebo for a defined period, with regular clinic visits for safety checks, blood pressure and heart rate monitoring, and simple questionnaires about mood and pain. At the start and at the end of the treatment period, each participant performs a six-minute walking test, in which the distance walked in six minutes is recorded.

Safety is assessed by recording any unwanted effects, checking basic blood work, and performing an electrocardiogram (ECG), a quick test that records the heart’s electrical activity. Functional outcomes include the walking distance, speed measured over a short distance, and self‑reported fatigue and quality of life. The study also tracks the number of falls and overall activity level to provide a broader picture of daily function.

The purpose of the study is to determine whether the new medicine works as well as the existing one. Participants will receive a series of these eye injections over several months and will have regular eye examinations. Vision will be checked using a test called BCVA, measured with an ETDRS chart, which is a standardized eye chart used to assess how well a person can read letters. Doctors will also look for signs of fluid inside the retina, called IRF and SRF, and will measure the size of the abnormal blood‑vessel area, known as CNV, using imaging methods such as FA and SD-OCT. Safety will be monitored throughout the study, including checking for any immune reactions called ADAs.

The purpose of the study is to determine if Eloralintide is more effective than a placebo at helping to change body weight. During the study, participants will be assigned to receive either the active medication or a placebo once every week. The process is double-blind, meaning that neither the participants nor the researchers know who is receiving the actual drug or the inactive substance until the study is complete. Participants will be monitored over a period of time to observe changes in weight and to ensure safety.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

During the study, volunteers will attend regular visits over an 18‑month period, beginning with a baseline assessment and followed by follow‑up visits roughly every six months. At each visit, blood samples will be taken to measure levels of several substances that indicate inflammation, such as IL-1β, IL-6, and TNFα, as well as markers of blood vessel health, clotting, oxidative stress, and cellular aging. Simple explanations of these markers will be provided, for example, describing them as signals that the body uses to show whether inflammation or stress is occurring. Additional tests will track changes in weight, blood sugar control, and cholesterol levels. The overall design allows researchers to compare the changes in these measurements between the Metformin group and the placebo group to see if the drug influences the biological processes associated with aging and inflammation.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

The purpose of the study is to determine which treatment approach provides a longer-lasting increase in platelet levels. Participants are assigned by chance to one of the two treatment groups and receive the assigned medication for several weeks. Throughout the study, regular blood tests are performed to check platelet counts, and participants attend clinic visits to monitor their health and any side effects.

The study flow includes an initial screening, the start of the assigned therapy, periodic follow‑up visits for blood sampling and safety checks, and a final assessment at the end of the treatment period. Any serious or unexpected problems are recorded, and the overall safety of the medications is closely observed.

The purpose of the study is to determine whether giving Radium-223 after the triplet regimen is feasible for patients with high‑volume disease. After completing the initial combination therapy, patients receive a series of Radium-223 injections, typically one every four weeks, with up to five doses planned. Throughout the treatment period, doctors check blood tests, scan images, and ask about pain and quality of life to track how well the therapy is tolerated and whether the cancer remains under control.

During the trial, patients will start treatment and then return for regular visits where doctors will check for side effects and perform imaging scans, such as CT or MRI, to see how the tumors are changing. The scans are evaluated using a standard set of rules called RECIST, which helps doctors decide whether the cancer is responding, staying the same, or getting worse. Treatment continues as long as it is tolerated and the disease does not progress, with follow‑up visits scheduled at set intervals to monitor health and tumor size.

The purpose of the study is to determine how effectively this drug combination can delay the need for additional cancer therapy. Participants receive the study tablets for up to two years while attending regular check‑ups where doctors monitor health, side effects, and any changes in the cancer. Safety is closely watched through routine tests and reporting of any adverse effects.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The main aim is to determine whether Brenipatide improves symptoms compared with placebo. Participants are assigned by chance to receive either the study drug or the placebo, and the trial is conducted in a double‑blind manner so that neither the participants nor the study staff know which treatment is administered. After a short screening period, injections are given regularly for several weeks, and participants attend clinic visits to report how they feel and to have safety checks.

Throughout the 16‑week period, the study records how many weeks each participant experiences a meaningful reduction in pain and stool difficulty, and it monitors any side effects. The collected information will help decide if the medicine is both effective and safe for people with this type of irritable bowel syndrome.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The purpose of the study is to determine whether oral semaglutide leads to greater weight loss compared with the placebo when combined with diet and exercise. Participants will take the assigned tablet every day for several months, attend regular clinic visits where their weight, waist size, blood pressure, and blood tests are checked, and report any side effects. The study will track changes in body weight and related health measures over the course of the trial.

The purpose of the study is to evaluate whether Rimonabant can improve functional independence, meaning the ability to perform everyday activities without assistance. Throughout the trial, researchers will monitor safety by checking for any side effects, changes in vital signs, and overall well‑being. Functional ability will be assessed using simple tools such as the Barthel Index, which measures how well a person can manage basic tasks like dressing, eating, and moving around, as well as other straightforward tests of walking and balance. The study does not involve any experimental procedures beyond taking the study tablets and attending the scheduled check‑ups.

Participants will receive one tablet each day for about nine months. Throughout the study they will visit the clinic regularly, where health care staff will collect a urine sample, usually the first morning urine, and perform a simple test that compares the protein level to a normal waste product to see how much protein is present. Blood samples will also be taken to understand how the body absorbs and clears the medication. Doctors will monitor safety by checking for any side effects, routine lab results, and vital signs during the visits.

The purpose of the study is to see if this immune modulation approach lowers the amount of virus in the blood compared with keeping the standard drug regimen. Participants will be assigned to one of the two adjustment strategies or to continue their current treatment, and their virus levels will be checked at the start and again after a few weeks. Additional blood tests will look at how the immune system responds to the virus, and the data will help determine whether the new strategies are effective.

The purpose of the study is to determine whether individuals with a favorable genetic and clinical background can maintain low levels of the virus after stopping medication. After an initial treatment period, the medication will be stopped in a process called analytical treatment interruption, and participants will be closely monitored for up to 24 weeks. Blood tests will measure the viral load (the amount of virus in the blood) and will also look at immune cells such as CD4 and CD8 lymphocytes and NK cells; laboratory techniques like flow cytometry and NGS will be used to study these cells and the virus that remains hidden in the body.

The purpose of the trial is to determine whether AZD8965 can reduce the loss of lung function compared with placebo, using the change in FVC (forced vital capacity, the amount of air exhaled forcefully after a deep breath) as the main measure over about 24 weeks. Participants will be screened, then randomly assigned to receive either the study drug or placebo for a six‑month period, with regular clinic visits for safety checks, blood samples, and simple breathing tests. Throughout the study, any side effects and overall health will be closely monitored.

The purpose of the study is to find out whether JNJ-78934804 can bring participants to a state of clinical remission (no noticeable symptoms) and an endoscopic remission (no visible inflammation when doctors look inside the gut with a camera) by week 48. Participants will receive a series of injections over about a year and will attend regular clinic visits where doctors check health, assess symptoms and may perform simple imaging to look at the gut. Throughout the study, neither the participants nor the treating doctors know which medication is being given, helping to keep the results unbiased.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

The purpose of the study is to determine whether nerandomilast can more effectively delay death or disease worsening compared with the placebo.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year. During this time, they will attend regular clinic visits where doctors will check skin thickness, lung function (including a test called FVC that measures how much air can be forced out of the lungs), physical ability, and overall health. The study will track any serious health events, changes in symptoms, and overall survival throughout the treatment period.

During the trial, each person will take the assigned tablets every day for about 40 weeks. Regular visits will include simple blood tests, such as the HbA1c test, which shows the average blood‑sugar level over the past few months, measurements of body weight, and checks of blood pressure. The schedule is designed to monitor how the medicines affect blood sugar, weight, and overall health while watching for any side effects.

The main goal of the trial is to see whether Lepodisiran can reduce the amount of plaque in the coronary arteries. Participants will receive a series of injections over several months and will have routine check‑ups that may include imaging scans to look at the arteries. Throughout the study, researchers will compare the changes in plaque size between those who receive Lepodisiran and those who receive the placebo, to determine if the drug can help lower the risk of future heart events.

The purpose of the study is to assess the safety and tolerability of the drug. In the first part, participants receive several doses that increase in amount over time; in the second part, all participants continue to receive the drug in an open‑label phase where both researchers and participants know the treatment. Throughout the trial, researchers monitor for side effects (AEs) and perform routine checks such as a heart test (ECG), laboratory analysis of blood and the fluid around the brain and spine (CSF), vital signs, weight and mental health screening. Blood and fluid samples are also taken to understand the drug’s pharmacokinetics, meaning how it is absorbed, distributed, and cleared from the body.

Participants attend regular clinic visits over several months, during which they receive the study medication, undergo the safety checks described above, and provide samples for analysis. The study does not provide any guarantee of benefit, and its primary aim is to gather information on how the drug is tolerated in people with this condition.

The purpose of the study is to identify the optimal amount of the medication and to evaluate its ability to shrink or stop the growth of the cancer (anti‑tumour activity). The research is conducted as a phase II trial, meaning it is designed to test different dose levels for safety and effectiveness after initial safety has been shown.

Participants receive a series of injections of the study drug into the tumor at scheduled visits, followed by regular medical examinations, imaging scans, and questionnaires that assess symptoms and overall well‑being. The study continues until the treatment plan is completed or until the disease progresses, with ongoing monitoring to record any side effects and changes in the tumor size.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

The research is divided into different parts. In Part A, researchers study how safe the medication is and how well patients tolerate it. In Part B, they examine how effective the medication is at stopping tumor growth. Some patients will receive AL102, while others will receive a placebo. The study also includes an extended treatment period where all participants can receive the active medication.

Throughout the study, doctors will monitor the size of tumors using medical imaging. They will also track any changes in symptoms and how patients feel while taking the medication. The medication is being tested at different dose levels to find the most effective and safe amount for treating desmoid tumors.